Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Collegium Pharmaceutical (COLL)
NASDAQ:COLL
RESEARCH TOOLSreports
Holding COLL?
Track your performance easily
COLL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$28.39 - $42.29
Previous CloseN/A
Volume233.62K
Average Volume (3M)471.90K
Market Cap
$1.08B
Enterprise Value$2.40B
Total Cash (Recent Filing)$153.22M
Total Debt (Recent Filing)$1.48M
Price to Earnings (P/E)14.4
Beta0.45
Next Earnings
Feb 20, 2025EPS Estimate
1.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.32
Shares Outstanding32,250,237
10 Day Avg. Volume525,964
30 Day Avg. Volume471,900
Standard Deviation0.12
R-Squared0.13
Alpha0.00316
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.25
Price to Cash Flow (P/CF)-20.70
P/FCF Ratio0.00
Enterprise Value/Market Cap2.22
Enterprise Value/Revenue4.01
Enterprise Value/Gross Profit7.36
Enterprise Value/Ebitda7.56
Forecast
1Y Price Target
$43.25Price Target Upside29.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Collegium Pharmaceutical News
PremiumCompany Announcements
Collegium Pharmaceutical Unveils 2025 Financial Projections
PremiumCompany Announcements
Collegium Pharmaceutical Reports Strong Q3 2024 Results
PremiumCompany Announcements
Collegium Pharmaceutical Appoints Vikram Karnani as CEOBulls Say, Bears Say
Bulls Say
Acquisition And DiversificationThe Ironshore deal diversifies the business from just pain and increases the growth and margin profile of the company.
Financial PerformanceCollegium reported record revenue and adj. EBITDA, and announced the appointment of new CEO, Vikram Karnani, previously head of commercial at Horizon Therapeutics.
Leadership ChangeThe key news of the earnings update is the CEO appointment of Vikram Karnani who comes from Amgen/Horizon with a rare disease commercial background.
Bears Say
Growth PotentialMaintain a Hold rating as more details on the growth potential and profitability of COLL's newly-expanded product portfolio are awaited.
Product StrategyAnother plan will downgrade both products to parity positions.
Sales PerformanceLower than expected sales in both Xtampza and the Nucynta franchise.
---
Ownership Overview
4.44% Insiders
37.98% Mutual Funds
0.90% Other Institutional Investors
24.03% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
COLL FAQ
What was Collegium Pharmaceutical’s price range in the past 12 months?
Collegium Pharmaceutical lowest stock price was $28.39 and its highest was $42.29 in the past 12 months.
What is Collegium Pharmaceutical’s market cap?
Collegium Pharmaceutical’s market cap is $1.08B.
When is Collegium Pharmaceutical’s upcoming earnings report date?
Collegium Pharmaceutical’s upcoming earnings report date is Feb 20, 2025 which is in 32 days.
How were Collegium Pharmaceutical’s earnings last quarter?
Collegium Pharmaceutical released its earnings results on Nov 07, 2024. The company reported $1.61 earnings per share for the quarter, beating the consensus estimate of $1.591 by $0.019.
Is Collegium Pharmaceutical overvalued?
According to Wall Street analysts Collegium Pharmaceutical’s price is currently Undervalued.
Does Collegium Pharmaceutical pay dividends?
Collegium Pharmaceutical does not currently pay dividends.
What is Collegium Pharmaceutical’s EPS estimate?
Collegium Pharmaceutical’s EPS estimate is 1.54.
How many shares outstanding does Collegium Pharmaceutical have?
Collegium Pharmaceutical has 32,250,237 shares outstanding.
What happened to Collegium Pharmaceutical’s price movement after its last earnings report?
Collegium Pharmaceutical reported an EPS of $1.61 in its last earnings report, beating expectations of $1.591. Following the earnings report the stock price went down -7.347%.
Which hedge fund is a major shareholder of Collegium Pharmaceutical?
Currently, no hedge funds are holding shares in COLL
---
Collegium Pharmaceutical Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.25 (29.69% Upside)
$43.25 (29.69% Upside)
Blogger Sentiment
Bullish
COLL Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 33.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 4.4%
Last 30 Days ▲ 4.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
1.86%
12-Months-Change
Fundamentals
Return on Equity
42.89%
Trailing 12-Months
Asset Growth
38.86%
Trailing 12-Months
Company Description
Collegium Pharmaceutical
Collegium Pharmaceutical, Inc. operates as a pharmaceutical company, which engages in the developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR. The Xtampza ER provides pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. The Nucynta ER for the treatment of chronic pain and neuropathic pain associated with diabetic peripheral neuropathy. The Nucynta IR is a release formulation of tapentadol indicated for the management of acute pain severe enough to require an opioid analgesic. The company was founded by Michael Thomas Heffernan in October 2003 and is headquartered in Stoughton, MA.
---
COLL Company Deck
---
COLL Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook, showcasing strong revenue growth and successful integration of the Ironshore acquisition, along with strategic wins in commercial coverage. However, challenges such as the decline in Nucynta revenue and anticipated prescription pressure from formulary removals were noted. Despite these challenges, the company's strategic growth initiatives and robust financial performance indicate a positive sentiment.Read More>---
COLL Stock 12 Month Forecast
Average Price Target
$43.25
▲(29.69% Upside)
Technical Analysis
Eagle Pharmaceuticals
―
Catalyst Pharma
―
MannKind
―
RedHill Biopharma
―
Protagonist Therapeutics
―
Supernus Pharmaceuticals
―
Best Analysts Covering COLL
1 Year
1 Year Success Rate
16/33 ratings generated profit
1 Year Average Return
+7.00%
upgraded a buy rating 10 days ago
Copying Serge Belanger's trades and holding each position for 1 Year would result in 48.48% of your transactions generating a profit, with an average return of +7.00% per trade.
---